Pfizer, the maker of drugs like Viagra and Lipitor may have
found a way to escape the US corporate income tax disadvantage.
Pfizer has proposed to buy AstraZeneca and this would allow
them to merge with the British company and reincorporate in Britain. Voila – a British company rather than a US
company. The transaction has initially
been rebuffed by AstraZeneca but the point is much broader than this one
transaction.
The stated reason is that the combined companies will have
economies of scale. But it would also
result in the surviving company being able to access tons of cash that is
overseas without paying the US tax that is due when those funds are moved to the US.
America’s top-line corporate tax rate is the highest in the
developed world. Granted in some
industries and circumstances, discounts have been granted to certain favored
businesses. But for a company that pays
the full tax bite, US corporate income taxes are frequently their biggest expense.
The net result is that the United States will lose jobs, and
tax revenue. What is not nearly as visible
are those new companies that are being incorporated outside the United States today
because they want to avoid the added tax bite in the US from the get-go.
No comments:
Post a Comment